A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept and laser for retinopathy of prematurity
<p><strong>Topic:</strong> To compare bevacizumab, ranibizumab, aflibercept and laser as primary therapies for retinopathy of prematurity (ROP) in terms of retreatment rate.</p> <p><strong>Clinical relevance:</strong> Anti-VEGF agents are increasingly used...
Main Authors: | Chang, ET, Josan, AS, Purohit, R, Patel, CK, Xue, K |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2022
|
Similar Items
-
The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis
by: Jing Chen, et al.
Published: (2023-10-01) -
Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis
by: Niza Alva, et al.
Published: (2023-08-01) -
Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01) -
Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
by: Tuncay Topal, et al.
Published: (2017-06-01) -
Efficacy of Aflibercept and Ranibizumab in the treatment of diabetic macular edema
by: Bing Wu, et al.
Published: (2023-08-01)